J.A. Schalken

694 total citations
31 papers, 535 citations indexed

About

J.A. Schalken is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J.A. Schalken has authored 31 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in J.A. Schalken's work include Bladder and Urothelial Cancer Treatments (7 papers), Cancer Research and Treatments (4 papers) and Prostate Cancer Treatment and Research (4 papers). J.A. Schalken is often cited by papers focused on Bladder and Urothelial Cancer Treatments (7 papers), Cancer Research and Treatments (4 papers) and Prostate Cancer Treatment and Research (4 papers). J.A. Schalken collaborates with scholars based in Netherlands, Japan and India. J.A. Schalken's co-authors include Yahya Tamimi, Ed Schuuring, F.M.J. Debruyne, H. Ewout Schaafsma, Egbert Oosterwijk, J.A. Witjes, R. Jeroen A. van Moorselaar, F M Debruyne, P P Bringuier and Jacqueline A. M. Vet and has published in prestigious journals such as Cancer Research, The Journal of Urology and Annals of Oncology.

In The Last Decade

J.A. Schalken

31 papers receiving 524 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.A. Schalken Netherlands 13 209 172 171 161 76 31 535
R R Hall United Kingdom 6 229 1.1× 204 1.2× 312 1.8× 135 0.8× 21 0.3× 9 654
Marie Gamarra United States 10 106 0.5× 132 0.8× 105 0.6× 53 0.3× 24 0.3× 18 372
Arndt Hartmann Germany 8 183 0.9× 238 1.4× 130 0.8× 137 0.9× 48 0.6× 13 575
Mitsuo Goto Japan 16 234 1.1× 128 0.7× 195 1.1× 70 0.4× 36 0.5× 58 606
Aaron C. Han United States 14 419 2.0× 87 0.5× 244 1.4× 145 0.9× 63 0.8× 27 783
Joël Gsponer Switzerland 11 213 1.0× 273 1.6× 242 1.4× 138 0.9× 11 0.1× 17 675
Carlos Olivier Spain 10 77 0.4× 116 0.7× 139 0.8× 88 0.5× 11 0.1× 27 379
Alfred Schauer Germany 14 309 1.5× 70 0.4× 213 1.2× 98 0.6× 107 1.4× 22 683
Timo Pietiläinen Finland 11 228 1.1× 79 0.5× 266 1.6× 73 0.5× 13 0.2× 16 539
Andreas Brunner Austria 13 164 0.8× 95 0.6× 159 0.9× 43 0.3× 23 0.3× 20 499

Countries citing papers authored by J.A. Schalken

Since Specialization
Citations

This map shows the geographic impact of J.A. Schalken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.A. Schalken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.A. Schalken more than expected).

Fields of papers citing papers by J.A. Schalken

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.A. Schalken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.A. Schalken. The network helps show where J.A. Schalken may publish in the future.

Co-authorship network of co-authors of J.A. Schalken

This figure shows the co-authorship network connecting the top 25 collaborators of J.A. Schalken. A scholar is included among the top collaborators of J.A. Schalken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.A. Schalken. J.A. Schalken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wilpe, Sandra van, Martijn H. den Brok, Harm Westdorp, et al.. (2024). Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial. Annals of Oncology. 35(12). 1126–1137. 14 indexed citations
2.
Witjes, J.A., J.L.J. Vriesema, Antoine G. van der Heijden, Godefridus J. Peters, & J.A. Schalken. (2003). Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Pigs. European Urology. 44(5). 615–619. 12 indexed citations
3.
Witjes, J. Alfred, Antoine G. van der Heijden, J.L.J. Vriesema, et al.. (2003). Intravesical Gemcitabine: A Phase 1 and Pharmacokinetic Study. European Urology. 45(2). 182–186. 35 indexed citations
4.
Dijk, Boukje A. C. van, Leo J. Schouten, Christina A. Hulsbergen‐van de Kaa, et al.. (2002). Risk factors, genetic predisposition and mutations in the VHL gene in sporadic renal cell carcinoma: The Netherlands Cohort Study.. PubMed. 156. 509–10. 1 indexed citations
5.
Mulder, P.H.M. de, J.A. Schalken, & Cora N. Sternberg. (2002). Treatment options in hormone resistant prostate cancer. Annals of Oncology. 13. 95–102. 5 indexed citations
6.
Schalken, J.A.. (1998). Molecular Diagnostics and Therapy of Prostate Cancer: New Avenues. European Urology. 34(Suppl. 3). 3–6. 9 indexed citations
7.
Smedts, Frank, et al.. (1998). Identification of intermediate cell types by keratin expression in the developing human prostate. (vol 34, pg 292, 1998). The Prostate. 35(2). 4 indexed citations
8.
Xue, Yan, et al.. (1998). Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): a marker of progression?. PubMed. 18(4A). 2679–84. 22 indexed citations
9.
Shimazui, Toru, et al.. (1998). Decreased Expression of alpha-Catenin is Associated With Poor Prognosis of Patients With Localized Renal Cell Carcinoma. The Journal of Urology. 160(5). 1955–1955. 1 indexed citations
10.
Shimazui, Toru, Egbert Oosterwijk, Hideyuki Akaza, et al.. (1998). Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma.. PubMed. 4(10). 2419–24. 27 indexed citations
11.
Poel, H.G. Van Der, M. E. Boon, E. C. M. Ooms, et al.. (1997). Conventional bladder wash cytology performed by four experts versus quantitative image analysis.. PubMed. 10(10). 976–82. 18 indexed citations
12.
Oosterwijk, Egbert, F.M.J. Debruyne, & J.A. Schalken. (1995). The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma.. PubMed. 22(1). 34–41. 31 indexed citations
13.
Peelen, W. P., et al.. (1992). Establishment and characterization of five new human renal tumor xenografts.. PubMed. 140(2). 483–95. 20 indexed citations
14.
Karthaus, Herbert F.M., Wouter F.J. Feitz, J.A. Schalken, et al.. (1992). Multidisciplinary evaluation of rat renal cell carcinoma.. PubMed. 1(6). 335–41. 2 indexed citations
15.
Schaafsma, H. Ewout, F. C. S. Ramaekers, H Robben, et al.. (1991). Cytokeratin expression patterns in metastatic transitional cell carcinoma of the urinary tract. An immunohistochemical study comparing local tumor and autologous metastases.. PubMed. 139(6). 1389–400. 31 indexed citations
17.
Roebroek, Anton, Gerard J.M. Martens, Ashley J. Duits, et al.. (1989). Differential expression of the gene encoding the novel pituitary polypeptide 7B2 in human lung cancer cells.. PubMed. 49(15). 4154–8. 19 indexed citations
18.
Oosterhof, G.O.N., et al.. (1989). The in vitro effect of electromagnetically generated shock waves (Lithostar) on the Dunning R3327 PAT-2 rat prostatic cancer cell-line. Urological Research. 17(1). 13–19. 45 indexed citations
19.
Peelen, W. P., et al.. (1988). In vitro antiproliferative efficacy of Interferon-alpha,-gamma and Tumor Necrosis Factor on two human renal tumor xenografts. Urological Research. 16(4). 309–314. 7 indexed citations
20.
Peelen, W. P., et al.. (1988). Effect of alpha‐ and gamma‐Interferon and tumor necrosis factor on colony formation of two human renal tumor xenografts in vitro. Seminars in Surgical Oncology. 4(3). 195–198. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026